Scholarlink

<p>The emergence of carbapenemase-producing <i>Enterobacterales</i> represents a significant clinical challenge. Resistance mechanisms involve carbapenemase production, porin and efflux pump alterations, penicillin-binding protein (PBP) modifications, and biofilm formation. This study characterizes a KPC-<i>producing Klebsiella pneumoniae</i> and a concurrent <i>Escherichia coli</i> isolate harboring the same resistance genes, with <i>E. coli</i> also exhibiting PBP3 mutations. Whole-genome sequencing and plasmid analysis identified an IncFII(K) plasmid carrying the <i>bla</i><sub>KPC-3</sub> gene. Both strains shared two resistance genes (<i>bla</i><sub>KPC-3</sub>, <i>bla</i><sub>OXA-9</sub>). <i>K. pneumoniae</i> contained a single copy of <i>bla</i><sub>KPC-3</sub> on Tn<i>4401a</i>, whereas <i>E. coli</i> carried two copies on separate Tn<i>4401a</i> transposons. Plasmid reconstruction revealed high homology (99.85%) with <i>E. coli</i> plasmid pECAZ147_KPC and <i>K. pneumoniae</i> plasmid pKPC. This suggests that transposon-mediated <i>bla</i><sub>KPC-3</sub> transfer between the two strains may have occurred via the same plasmid. Moreover, <i>E. coli</i> harbored PBP3 mutations (A233T, I332V), which have been previously linked to increased ceftazidime MICs and two missense mutations in <i>marR</i>. Despite carrying two copies of the <i>bla</i><sub>KPC-3</sub> gene, along with <i>marR</i> and PBP3 mutations, our <i>E. coli</i> isolate did not exhibit a significant increase in ceftazidime/avibactam MIC. This phenomenon could be explained by avibactam’s ability to bind to <i>E. coli</i> PBP2, potentially compensating for the reduced binding of ceftazidime to the mutated PBP3.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Potential role of avibactam in restoring susceptibility in Escherichia coli with two copies of blaKPC-3 and PBP3 mutations

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Simone Giuliano,
  • Valeria Fox,
  • Sara Ferin,
  • Luca Martini,
  • Jacopo Angelini,
  • Michela Bulfoni,
  • Beatrice Krpan,
  • Nicolò Gualandi,
  • Chiara Moreal,
  • Carlo Federico Perno,
  • Paola Bernaschi,
  • Ciro Di Gennaro,
  • Celeste Arcamone,
  • Sara Turco,
  • Maria Cristina Stanziola,
  • Rosa Manzi,
  • Francesco Curcio,
  • Corrado Pipan,
  • Carlo Tascini

摘要

The emergence of carbapenemase-producing Enterobacterales represents a significant clinical challenge. Resistance mechanisms involve carbapenemase production, porin and efflux pump alterations, penicillin-binding protein (PBP) modifications, and biofilm formation. This study characterizes a KPC-producing Klebsiella pneumoniae and a concurrent Escherichia coli isolate harboring the same resistance genes, with E. coli also exhibiting PBP3 mutations. Whole-genome sequencing and plasmid analysis identified an IncFII(K) plasmid carrying the blaKPC-3 gene. Both strains shared two resistance genes (blaKPC-3, blaOXA-9). K. pneumoniae contained a single copy of blaKPC-3 on Tn4401a, whereas E. coli carried two copies on separate Tn4401a transposons. Plasmid reconstruction revealed high homology (99.85%) with E. coli plasmid pECAZ147_KPC and K. pneumoniae plasmid pKPC. This suggests that transposon-mediated blaKPC-3 transfer between the two strains may have occurred via the same plasmid. Moreover, E. coli harbored PBP3 mutations (A233T, I332V), which have been previously linked to increased ceftazidime MICs and two missense mutations in marR. Despite carrying two copies of the blaKPC-3 gene, along with marR and PBP3 mutations, our E. coli isolate did not exhibit a significant increase in ceftazidime/avibactam MIC. This phenomenon could be explained by avibactam’s ability to bind to E. coli PBP2, potentially compensating for the reduced binding of ceftazidime to the mutated PBP3.